Based on these results, we speculated that GC patients with the CSC4 pattern may benefit from combination treatment with the blockade targets on adhesion‐related signaling pathways, and CSC1 patterns may benefit from blockade targets on tumor metabolism signaling. This evidence concerns the gene TMEM63C and gastric cancer.